plerixafor,busulfan
otsuka,sanofi,sangamo therapeutics
['precizn1']
#sangamo reported summary of updated preliminary safety, tolerability and efficacy results from the phase 1/2 #precizn1 study of #bivv003 presented at #ash22 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.